

JC20 Rec'd PCT/US 28 SEP 2005

ATTORNEY DOCKET NO.: 2003080-0205 (SK-1071-US2)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Huang et al.	Examiner: TBA
Serial No:	To Be Assigned	Group Art Unit: TBA
Filing Date:	September 28, 2005	
Corresp. To:	PCT/US2004/009380	
Int. Filing Date:	March 26, 2004	
Earliest Priority:	March 28, 2003	
Title:	MIGRASTATIN ANALOG COMPOSITIONS AND USES THEROF	

Mail Stop: PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicant requests consideration of this Information Disclosure Statement.

Type of Statement

The present Information Disclosure Statement is:

☒ An *original* Information Disclosure Statement; or

☐ A *supplemental* Information Disclosure Statement.

CERTIFICATE OF MAILING

"Express Mail" mailing label number EV 694840555 US
Date of Deposit: September 28, 2005

I hereby certify that this correspondence is being deposited with the United States Postal Service as "*Express Mail Post Office to Addressee*" service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Signature

Ruth Dolan

Typed Name

Compliance with 37 CFR § 1.97

The present Information Disclosure Statement is being filed:

☒ Pursuant to 37 CFR § 1.97(b); no fee or certification is required:

☐ Within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d);

☒ Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application;

☐ Before the mailing of a first Office action on the merits; or

☐ Before the mailing of a first Office action after the filing of a request for continued examination under § 1.114.

☐ Pursuant to 37 CFR § 1.97(c) after the dates listed above but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *either*:

☐ Certifies that *either*:

☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the

knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement; or

☐ Includes herewith the fee set forth in § 1.17(p),

☐ Pursuant to 37 CFR § 1.97(d), after the mailing date of any final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *both*:

☐ Certifies that *either*:

☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or

- ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement; and
- ☐ Includes herewith the fee set forth in § 1.17(p).

Content of the Information Disclosure Statement

Applicant hereby makes of record in the above-identified application the reference(s) listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Applicant includes copies of references as indicated below:

- ☒ A copy of each cited reference not indicated with an asterisk is included;

- ☐ Copies of references indicated with an asterisk on the attached form PTO-1449 are not included pursuant to 37 CFR § 1.98(d) because they were previously provided to the United States Patent Office in an Information Disclosure Statement that complies with 37 CFR § 1.98(a)-(c) and was submitted in the following patent application that is relied upon in the present case for an earlier effective filing date under 35 USC § 120:

Serial Number	Filing Date	Status

- ☐ Copies of English translations of one or more non-English references are included.

Applicant hereby makes the following additional information of record in the above-identified application:

Applicant certifies that the Information Disclosure Statement *either*:

- ☒ Does not contain non-English language citations;
- ☐ Includes one or more translations of a non-English citation; or
- ☐ Does contain non-English language citations, of which the following is a concise explanation:

Remarks

The submission of this Information Disclosure Statement should not be construed as a representation that a search has been made.

The submission of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56(b) .

JC20 Rec'd PCT/PTO 28 SEP 2005

The submission of this Information Disclosure Statement shall not be construed as a representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 USC §102.


It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark Office during the examination of this application; and
3. The citations for the patent(s) and publication(s) be printed on any patent which issues from this application.

Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited reference(s).

Dated: September 28, 2005

Respectfully submitted,



Nadège M. Lagneau, Ph.D.
Agent for Applicant
Reg. No.: 51,908

CHOATE, HALL & STEWART, LLP
2 International Place
Boston, Massachusetts 02110
(617) 248-5000
(617) 248-4000

Form PTO-1449 (REV. 8-83) INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>	U.S. Department of Commerce Patent and Trademark Office		Atty. Docket: 2003080-0205 (SK-1071-US2)	In re Application No. <div style="font-size: 1.5em; font-weight: bold;">10/551152</div>	
			<div style="border: 1px solid black; padding: 2px;"> JC20 Rec'd PCT/PTO 28 SEP 2005 </div>		
			Applicant: Huang, et al.	Filing Date: September 28, 2005	

U.S. PATENT DOCUMENTS

Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass

U.S. PATENT APPLICATIONS

Examiner's Initials:	Serial Number:	Applicant:	Filing Date:	Group:	Art Unit:
	2002/0119937 A1	Khosla, <i>et al.</i>	August 17, 2001		

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Document No.	Country	Date	Translation	
				Yes	No

OTHER DOCUMENTS

Examiner's Initials	Citation (Including Author, Title, Date, Pertinent Pages, Etc.)
	Gaul, et al. "Synthesis of the Macrolide Core of Migrastatin" <i>Tetrahedron Letters</i> 43 : 9039-9042, 2002.
	Nakae, et al., "Migrastatin, a Novel 14-Membered Lactone" <i>Journal Of Antibiotics</i> 53(10) : 1228-1230, 2000.
	Nakamura, et al., "Absolute Configuration Of Migrastatin, A Novel 14-Membered Ring Macrolide" <i>Journal Of Antibiotics</i> 55(4) : 442-444, 2002.
	Takemoto, et al., "Migrastatin, A Novel 14-Membered Ring Macrolide, Inhibits Anchorage-Independent Growth of Human Small Cell Lung Carcinoma Ms-1 Cells" <i>Journal Of Antibiotics</i> 54(12) : 2001.
	Woo, et al., "Migrastatin And A New Compound, Isomigrastatin, From Streptomyces Platensis" <i>Journal Of Antibiotics</i> 55(2) : 141-146, 2002.
	International Search Report Corresponding to PCT Appl. No. PCT/US2004/009380

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.